85 related articles for article (PubMed ID: 21083606)
1. HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target.
Han CP; Hsu JD; Yao CC; Lee MY; Ruan A; Tyan YS; Yang SF; Chiang H
Histopathology; 2010 Nov; 57(5):763-4. PubMed ID: 21083606
[No Abstract] [Full Text] [Related]
2. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
3. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
[TBL] [Abstract][Full Text] [Related]
4. Human epidermal growth factor receptor 2 overexpression and amplification in mucinous tumours of ovary.
Gilks CB; McAlpine J
Histopathology; 2011 Jun; 58(7):1173-4. PubMed ID: 21707717
[No Abstract] [Full Text] [Related]
5. III. Ovarian cancer 2. Treatment strategy for mucinous adenocarcinoma of the ovary.
Gan To Kagaku Ryoho; 2012 Feb; 39(2):202-205. PubMed ID: 22545288
[No Abstract] [Full Text] [Related]
6. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis.
McCaughan H; Um I; Langdon SP; Harrison DJ; Faratian D
J Clin Pathol; 2012 Jul; 65(7):670-1; author reply 671-2. PubMed ID: 22412045
[No Abstract] [Full Text] [Related]
7. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.
Chay WY; Chew SH; Ong WS; Busmanis I; Li X; Thung S; Ngo L; Lim SL; Lim YK; Chia YN; Koh E; Pang C; Soh LT; Wang J; Ho TH; Tay SK; Lim-Tan SK; Lim KH; Chia JW; Goh LK
PLoS One; 2013; 8(4):e61565. PubMed ID: 23620766
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic options for mucinous ovarian carcinoma.
Gorringe KL; Cheasley D; Wakefield MJ; Ryland GL; Allan PE; Alsop K; Amarasinghe KC; Ananda S; Bowtell DDL; Christie M; Chiew YE; Churchman M; DeFazio A; Fereday S; Gilks CB; Gourley C; Hadley AM; Hendley J; Hunter SM; Kaufmann SH; Kennedy CJ; Köbel M; Le Page C; Li J; Lupat R; McNally OM; McAlpine JN; Pyman J; Rowley SM; Salazar C; Saunders H; Semple T; Stephens AN; Thio N; Torres MC; Traficante N; Zethoven M; Antill YC; Campbell IG; Scott CL
Gynecol Oncol; 2020 Mar; 156(3):552-560. PubMed ID: 31902686
[TBL] [Abstract][Full Text] [Related]
9. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
[TBL] [Abstract][Full Text] [Related]
10. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
McAlpine JN; Wiegand KC; Vang R; Ronnett BM; Adamiak A; Köbel M; Kalloger SE; Swenerton KD; Huntsman DG; Gilks CB; Miller DM
BMC Cancer; 2009 Dec; 9():433. PubMed ID: 20003286
[TBL] [Abstract][Full Text] [Related]
11. [Amplification of C-erB2 gene in ovarian cancer].
Zhang GL; Zu KL; Yu SY
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):401-3, 444. PubMed ID: 8001415
[TBL] [Abstract][Full Text] [Related]
12. The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study.
Tsai WC; Lee MY; Chen FL; Wang PH; Lin WL; Ruan A; Li YJ; Wang SC; Chiang H; Han CP
Arch Gynecol Obstet; 2011 Sep; 284(3):721-9. PubMed ID: 21046136
[TBL] [Abstract][Full Text] [Related]
13. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
14. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma.
Ramieri MT; Murari R; Botti C; Pica E; Zotti G; Alo PL
Anticancer Res; 2010 Apr; 30(4):1287-92. PubMed ID: 20530441
[TBL] [Abstract][Full Text] [Related]
15. Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma.
Chan OT; Chen ZM; Chung F; Kawachi K; Phan DC; Himmelfarb E; Lin F; Perry A; Wang HL
Am J Clin Pathol; 2010 Dec; 134(6):880-5. PubMed ID: 21088150
[TBL] [Abstract][Full Text] [Related]
16. Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells.
Chuang TC; Hsu SC; Cheng YT; Shao WS; Wu K; Fang GS; Ou CC; Wang V
Cancer Lett; 2011 Dec; 311(1):11-9. PubMed ID: 21757288
[TBL] [Abstract][Full Text] [Related]
17. SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer.
Hsueh SP; Hsu WB; Wen CC; Wang WB
Cancer Gene Ther; 2011 Dec; 18(12):859-70. PubMed ID: 21869825
[TBL] [Abstract][Full Text] [Related]
18. [Study of the amplification and expression of c-erbB2 oncogene in epithelial ovarian tumors].
Hou Y; Wang M; Liu W
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):426-8. PubMed ID: 9387293
[TBL] [Abstract][Full Text] [Related]
19. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
[TBL] [Abstract][Full Text] [Related]
20. [New technology of diagnosis of ovarian cancer].
Terashima Y
Gan No Rinsho; 1988 Aug; 34(10):1427-31. PubMed ID: 2845169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
